Celts welcome Celgene’s Patient access scheme for Vidaza, too
This article was originally published in Scrip
Celgene has finally secured a recommendation in Scotland for its bone marrow drug Vidaza (5-azacitidine) for treating myelodysplastic syndrome and leukaemia with a patient access scheme. The company eventually won a recommendation in England with the same tactic.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.